Most cells undergo apoptosis through the intrinsic pathway. This is dependent on mitochondrial outer membrane permeabilisation (MOMP), which is mediated by the pro-apoptotic Bcl-2 family proteins, Bax and Bak. During apoptosis, Bax translocates from the cytosol to the outer mitochondrial membrane (OMM), wherein it contributes to the formation of pores to release cytochrome-c. However, it remains unclear whether Bax translocation is sufficient to bring about MOMP or whether Bax requires further signals on the OMM to be fully activated. We have previously shown that during mammary epithelial cell anoikis, Bax translocation does not commit cells to MOMP and detached cells are rescued if survival signals from the extracellular matrix (ECM) are restored. These findings implied that a second signal is required for mitochondrial Bax to fully activate and cause MOMP. We now identify p38MAPK (mitogen-activated protein kinase) as this necessary signal to activate Bax after its translocation to mitochondria. The inhibition of p38MAPK did not prevent Bax translocation, but its activity was required for mitochondrial Bax to bring about MOMP. p38MAPK was activated and recruited to a high molecular weight mitochondrial complex after loss of ECM attachment. Artificially targeting p38MAPK to the OMM increased the kinetics of anoikis, supporting a requirement for its mitochondrial localisation to regulate Bax activation and drive commitment to apoptosis. Metazoan cells are pre-programmed to undergo apoptosis in response to becoming damaged or losing essential survival signals. Apoptosis in response to these cellular stresses is initiated through the intrinsic, or mitochondrial, pathway.
Metazoan cells are pre-programmed to undergo apoptosis in response to becoming damaged or losing essential survival signals. Apoptosis in response to these cellular stresses is initiated through the intrinsic, or mitochondrial, pathway. 1 During intrinsic apoptosis, mitochondrial outer membrane permeabilisation (MOMP) results in the release of proteins, such as cytochrome-c and second mitochondrial activator of caspases (Smac)/Diablo, which activate the caspases to drive cell death. The release of cytochrome-c and Smac/Diablo is an extremely rapid event, with mitochondria throughout the cell releasing their contents within a few minutes of MOMP first commencing. 2, 3 The resulting activation of caspases occurs immediately and cell death is complete within a few minutes. After MOMP, cells rapidly lose viability, even if caspase activation is inhibited. Thus, MOMP represents a point at which cells cannot be rescued from an apoptotic fate.
The Bcl-2 family of proteins regulates MOMP. 4 These are characterised by a number of shared regions of sequence homology, the Bcl-2 Homology (BH) domains. Pro-survival members, such as Bcl-2 and Bcl-X L , share BH-domains 1-4. In contrast, the pro-apoptotic proteins, Bax and Bak, only posses BH-domains 1, 2 and 3. A third group of Bcl-2 proteins are the BH3-only proteins, which function by sensing survival and stress signals, and transmit these to the pro-and antiapoptotic multi-domain proteins. 5 The multi-domain proapoptotic proteins, Bax and Bak, are expressed in virtually all tissues, and are absolutely required for MOMP to occur. 6 Cells derived from mice in which Bax and Bak are genetically deleted are resistant to a wide range of apoptotic stimuli. Mitochondrial Bax and Bak are thought to mediate cytochrome-c release by forming pores in the outer mitochondrial membrane (OMM).
Many cells require attachment to the correct extracellular matrix (ECM) to suppress apoptosis. 7 Apoptosis caused by loss of ECM-dependent survival signals is known as anoikis. Loss of sensitivity to anoikis has been shown to directly contribute to the ability of tumour cells to metastasise. 8 We have previously shown that Bax associates with mitochondria rapidly after detachment of mammary epithelial cells (MECs) from ECM. 9, 10 However, translocation of Bax can precede MOMP by a considerable amount of time, and can even be reversed if cells are able to reattach to ECM before becoming committed to apoptosis. MOMP requires further conformational changes in Bax that occur concomitantly with cytochrome-c release. This suggests that distinct signals regulate both the initial association of Bax with the OMM and its subsequent activation to induce MOMP. 11 Here, we identify a role for p38 mitogen-activated protein kinase (p38MAPK) in regulating Bax-dependent MOMP during anoikis. We show that after detachment of MECs from ECM, p38MAPK becomes activated and associated with the mitochondrial fraction. This p38MAPK activity is not required for Bax to translocate to mitochondria. Instead, p38MAPK regulates subsequent Bax activation, controlling MOMP and commitment to apoptosis.
Results
p38MAPK is required for MECs to undergo anoikis. We have previously shown that, after detachment of MECs from ECM, Bax rapidly redistributes to mitochondria. 10 In adherent MECs, GFP-Bax shows a cytosolic distribution (Figure 1a ). In contrast, detachment for just 15 min results in GFP-Bax associating with mitochondria, indicated by co-localisation with cytochrome-c. Identical results are obtained if the distribution of endogenous Bax is examined by subcellular fractionation (Figure 1b ). Prolonged detachment from ECM is required before loss of mitochondrial cytochrome-c and apoptotic nuclear morphology is observed (Figure 1a and b; Figure 6a ). We found that if MECs that had been detached for 30 min were allowed to reattach to ECM, endogenous Bax was lost from the mitochondrial fraction (Figure 1c ). These data, together with our previously published observations, suggest that after Bax translocation, a second signal is required before it activates and forms the MOMP-inducing pore.
To identify signalling pathways regulating this second event, we examined known survival pathways previously linked to adhesion signalling. MECs were either left adherent or detached from ECM for various time periods, and phosphorylation of several signalling enzymes was examined by immunoblotting ( Figure 2a) . We have previously shown that focal adhesion kinase (FAK) regulates anoikis in MECs, 14 and as expected its activation, judged by phosphorylation on tyrosine 397, is turned off within 15 min of cells detaching from ECM. Paxillin, a downstream substrate of FAK, becomes dephosphorylated within the same time period. When we looked at MAPK signalling, we observed that although ERK remained activated throughout, both JNK and p38MAPK became activated after detachment. Furthermore, their activation, as judged by phosphorylation on the threonine and tyrosine residues within the activation loop, increased significantly with prolonged detachment from ECM.
To test the requirement for p38MAPK and JNK activity for MEC anoikis, we pre-incubated cells with either JNK (SP600125) or p38MAPK (SB203580) inhibitors before detaching them from ECM for the indicated time periods (Figure 2b) . Apoptosis, as judged by nuclear morphology, was unaffected by inhibition of JNK compared with untreated cells. In contrast, SB203580 inhibited anoikis significantly over the time course investigated. To confirm this, we immunoblotted cell lysates from adherent or detached cells treated with SB203580 or DMSO for active caspase 3 ( Figure 2c ). No active caspase 3 was detected in adherent cells. In detached cells, the amount of active caspase 3 was noticeably reduced when p38MAPK was inhibited. To confirm the effectiveness of SB203580, MECs were treated with anisomycin, a potent activator of p38MAPK with or without pre-incubation with SB203580. Lysates were then prepared and immunoblotted for phospho-Hsp27 (Figure 2d ). SB203580 completely inhibited anisomycin-induced Hsp27 phosphorylation. We asked whether p38MAPK activity was required for MECs' apoptosis in response to other stimuli. MECs were treated with anisomycin, the EGF receptor inhibitor, Iressa or UV irradiation, in the absence or presence of SB203580. Apoptosis was observed by immunoblotting for activated caspase 3 (Supplemental Figure 1) . SB203580 inhibited caspase activation in response to all three stimuli.
We tested two siRNA duplexes targeted to p38MAPKa. MECs were transfected with each p38MAPKa siRNA or a control duplex, and immunoblotted using either a total p38MAPK antibody or the one specific for p38MAPKa ( Figure 3a) . One duplex (siRNA p38a-13) reduced expression of p38MAPKa by 70%. The reduction in total p38MAPK was around 50%, suggesting that another isoform, probably p38MAPKb, was also expressed. We were unable to directly test expression of p38MAPKb, as we could not find an antibody that detected the endogenous protein (data not shown). When we examined detachment-induced p38MAPK phosphorylation, this was almost completely abolished in MECs transfected with siRNA p38a-13, but not with the control siRNA ( Figure 3b ). Detachment-induced phosphorylation of Hsp27 was also reduced. We examined apoptosis by immunoblotting siRNA-transfected cells, detached for various time periods, using anti-active caspase 3 ( Figure 3c ). siRNA p38a-13 inhibited detachment-induced activation of caspase 3, confirming the requirement for p38MAPK in MEC anoikis. siRNA knockdown of p38MAPK did not affect the adhesiondependent phosphorylation of FAK. However, it did reduce the small amount of active caspase 3 seen in adherent cells, suggesting that activation of p38MAPK is also controlling the basal level of apoptosis in these cells.
p38MAPK associates with mitochondria during anoikis. We compared the phosphorylation of p38MAPK and known downstream effectors after detachment from ECM or treatment with anisomycin ( Figure 4a ). Anisomycin resulted in more robust phosphorylation of p38MAPK than that seen after detachment, but phosphorylation of Hsp27 was observed after either treatment. Interestingly, phosphorylation of the transcription factor ATF2 occurred in response to anisomycin, but not after detachment from ECM. Phosphorylation of a restricted set of substrates suggested that p38MAPK might be recruited to a specific subcellular compartment after loss of ECM attachment. To determine whether this was the case, we isolated cytosolic and mitochondrial fractions from MECs that were either left adherent, detached from ECM for 60 min, or detached for 60 min and then replated onto ECM ( Figure 4b ). As previously shown, detachment from ECM resulted in Bax associating with the mitochondrial fraction. Reattachment to ECM resulted in loss of Bax from the mitochondria. Detachment also brought about an accumulation of p38MAPK in the mitochondrial fraction, and this was also reversed if MECs were allowed to reattach to ECM. Interestingly, phosphorylated p38MAPK was exclusively present in the membrane fraction. To confirm mitochondrial localisation, we coexpressed in MECs a V5-epitope-tagged p38MAPK along with a mitochondrial marker (Supplemental Figure 2 ). After detachment from ECM, we observed colocalisation of V5-tagged p38MAPK with mitochondria. We asked whether activation of p38MAPK by upstream MKKs was sufficient to induce its translocation to mitochondria. Cells were transiently transfected with expression vectors for either an active MKK6 (MKK6Glu) or an inactive form (MKK6Ala). Cells were left adherent or detached for 30 min, and cytosolic and membrane fractions were prepared. Immunoblotting indicated that, although transient expression of MKK6Glu resulted in phosphorylation of endogenous p38MAPK, this was present in the cytosol of the adherent cells and was not recruited to the membrane fraction ( Figure 4c ; compare lanes 5 and 11). Even in the presence of MKK6Glu, detachment from ECM was required for the association of phosphorylated p38MAPK with the mitochondrial fraction (Figure 4c ; compare lanes 6 and 12). Identical results were observed with an active MKK3 (data not shown). Thus, ECM-withdrawal was necessary for translocation of p38MAPK to mitochondria.
As MAPKs can be recruited to specific subcellular compartments through scaffold proteins, we asked whether p38MAPK was associated with other molecules in the mitochondrial fraction in detached cells. We have recently shown, using BN-PAGE, that a number of Bcl-2 family proteins are recruited into high molecular weight complexes on mitochondria. 13 We used BN-PAGE to examine the native molecular weight of activated p38MAPK in detached cells. Mitochondrial fractions were prepared from MECs after detachment from ECM for 1 h. These were then separated by 2D BN-PAGE and immunoblotted for phospho-p38MAPK p38MAPK activity is required for MOMP. As p38MAPK was recruited to the mitochondrial fraction concomitant with Bax, we asked whether it regulated Bax translocation. MECs transiently expressing YFP-Bax were left adherent or detached from ECM for 15 min, either with or without pretreatment with SB203580. Inhibiting p38MAPK had no effect on the detachment-induced co-localisation of YFP-Bax and on the mitochondrial heat shock protein 70 (mtHsp70) (Figure 5a ). We examined translocation of endogenous Bax in detached MECs after p38MAPK inhibition by subcellular fractionation (Figure 5b ). Treatment with SB203580 resulted in a small amount of phospho-p38MAPK being detected in the cytosol. However, there was no effect on the recruitment of Bax to the membrane fraction. We also examined the distribution of Bid and Bcl-X L (Figure 5c ). Inhibiting p38MAPK had no effect on the redistribution of Bid after detachment. Similarly, there was no alteration in the membrane association of Bcl-X L .
We have recently shown that the Bax activation step associated with MOMP is a distinct regulatory step from its translocation. 11 As p38MAPK did not regulate Bax translocation, we asked whether it had a role in its subsequent activation. MECs treated with either DMSO or SB203580 were detached from ECM for various time periods. Cells were fixed and immunostained for cytochrome-c, and the number of The kinetics of progression to MOMP can be increased by overexpressing YFP-Bax in MECs (Figure 6b ). In cells overexpressing YFP-Bax, a significant increase in MOMP was observed after 4 h detachment. However, MOMP in YFPBax overexpressing cells was also inhibited by SB203580. We have recently shown that mutating proline 13 in Bax to alanine results in a protein that seems to drive cells through MOMP without any delay after loss of adhesion. We expressed YFPBaxP13A in MECs and treated them with SB203580. Surprisingly, we found that even this more readily activated form of Bax required p38MAPK activity to induce MOMP (Figure 6c ).
Bax activation is associated with the exposure of cryptic Nterminal epitopes. 15 We have shown that, during anoikis, exposure of these epitopes occurs not when Bax initially translocates to the OMM but during MOMP. 11 MECs transiently expressing YFP-Bax were left adherent or detached from ECM in the presence or absence of SB203580. Cells were then immunostained for exposure of the Bax N-terminal epitope (Figure 6d) . In adherent cells, YFP-Bax was diffuse and did not show epitope exposure. In agreement with our previous results, after detachment in the absence of SB203580, cells that showed apoptotic nuclei stained positively for anti-Bax N20. However, cells that did not show apoptotic morphology did not stain with anti-Bax N20, even though Bax had a punctate, mitochondrial distribution. Cells detached in the presence of SB203580 showed mitochondrial Bax, but did not show Nterminal epitope exposure or apoptotic nuclei. We also asked whether p38MAPK was required for the formation of the high molecular weight Bax complexes. BN-PAGE and immunoblotted for Bax (Figure 6e) . Interestingly, the membrane-associated 200-kDa complexes of Bax were unaffected by inhibition of p38MAPK, suggesting that these form before Bax activation and N-terminal epitope exposure, in agreement with our previous data. 13 Together, these results suggest that Bax activation after its translocation to the OMM requires p38MAPK activity.
p38MAPK association with mitochondria drives MEC commitment to apoptosis. We wanted to determine whether p38MAPK recruitment to mitochondria drove MECs through to the commitment point of apoptosis. Overexpression of p38MAPK or activated MKK6 did not result in apoptosis (data not shown). As activation of p38MAPK was insufficient to drive its association with the mitochondrial fraction, we decided to target it constitutively to the OMM. We generated YFP-tagged forms of p38MAPK a and b isoforms onto which we had attached the tail anchor sequence of Bcl-X L (YFP-p38aXT and YFP-p38bXT). YFPp38aXT and YFP-p38bXT colocalised with mtHsp70, indicating mitochondrial targeting (Figure7a and data not shown). Immuoblotting indicated that YFP-XT, YFP-p38aXT and YFP-p38bXT were expressed at similar levels, as was a non-targeted YFP-p38a (Figure 7b) . In adherent cells, overexpression of YFP-p38aXT, YFP-p38bXT or YFP-p38a with monomeric red fluorescent protein (mRFP)-XT did not result in phosphorylation on ser180/tyr182. However, coexpression with mRFP-MKK6GluXT resulted in a significant increase in the phosphorylation of all three YFPp38 constructs.
We next asked whether expression of mitochondrialtargeted p38MAPK altered the kinetics of apoptosis after detachment from ECM. MECs expressing YFP-p38aXT, YFPp38bXT or YFP-XT were either left adherent or detached for various time periods. Apoptosis was quantified by immunostaining for active caspase 3 or by examining nuclear morphology ( Figure 7 c and d) . There was no significant increase in the amount of apoptosis in adherent cells expressing YFP-p38aXT or YFP-p38bXT compared with that in YFP-XT. However, after detachment from ECM, both YFPp38aXT and YFP-p38bXT increased the rate of apoptosis, the a isoform having the most significant effect. We asked whether the membrane targeting was important for this effect on anoikis by expressing either YFP-p38aXT or the nontargeted YFP-p38a. There was no increase in apoptosis seen with expression of either protein in adherent cells (Figure 7e ). After detachment from ECM for 6 h expression, both YFPp38XT and YFP-p38a increased the amount of apoptosis. However, this was significantly greater (Po0.001) in the OMM-targeted YFP-p38XT.
Finally, we asked whether p38MAPK activation on mitochondria regulated MEC commitment to apoptosis. We have previously described an assay to measure apoptosis commitment after MEC detachment from ECM, which uses the ability of cells to be rescued from anoikis if adhesion signals are restored before they commit to apoptosis. 11 MECs were detached from ECM for 15 min and then allowed to reattach for 5 h, after which those cells that had committed to apoptosis would be found in the supernatant and those rescued would remain adherent. We transiently expressed in MECs YFP-XT, YFP-p38aXT or YFP-p38bXT, along with either mRFP-XT or mRFP-MKK6GluXT. After 5 h of reattachment, the ratio of transfected cells in the supernatant to those still adherent was determined (Figure 7f) . Expression of either of the YFPp38XT isoforms alone did not increase the number of cells that had committed to apoptosis after 15 min detachment, with the Cells were allowed to reattach for 5 h, after which the ratio of transfected cells in the supernatant (det) to those that had reattached (att) was calculated. The higher ratio of det:att indicates that more number of cells had committed to apoptosis and could not be rescued by reattachment to ECM. *Indicates significance by ANOVA. n/s indicates not significant same ratio of detached to attached cells seen with expression of YFP-XT. Thus, although overexpressing mitochondrialtargeted p38MAPK increased the rate of anoikis in MECs, it alone was insufficient to cause commitment to apoptosis after just 15 min detachment from ECM. We had seen relocalisation of phosphorylated MKK3 or MKK6 to mitochondria (data not shown). We, therefore, speculated that to accelerate commitment, we would need to force the recruitment of not only p38MAPK but also the activating MKK as well. In support of this, coexpressing mRFP-MKK6GluXT along with either YFP-p38aXT or YFP-p38bXT significantly increased the number of MECs that were committed to apoptosis after just 15 min detachment. These data indicate that activation of p38MAPK on mitochondria can alter the kinetics of MECs' commitment to apoptosis.
Discussion
The activation of the multi-domain pro-apoptotic Bcl-2 protein, Bax, is a critical event in the intrinsic pathway for cell death. The biochemical pathways that regulate Bax on mitochondria were recently described as 'the Holy Grail'. 4 In this paper, we show a role for p38MAPK in such a pathway during epithelial cell anoikis. In particular, we show that p38MAPK activity is essential for the Bax-dependent commitment of MECs to apoptosis. Loss of epithelial/ECM adhesion resulted in the recruitment of activated p38MAPK to the mitochondrial fraction. Detachment-induced p38MAPK activation was not required for Bax translocation to the OMM or its association with high molecular weight complexes. However, inhibiting p38MAPK activity protected cells from anoikis by preventing Bax-dependent MOMP. Mitochondrial p38MAPK was found to be associated with a high molecular weight complex, suggesting that it forms a regulatory scaffold during anoikis.
Bax activation involves a series of conformational changes, including reorientation of the C-terminal tail anchor, exposure of otherwise cryptic N-terminal antibody epitopes and its association with high molecular weight complexes. 10, [15] [16] [17] [18] [19] [20] During this process, Bax translocates from the cytosol to mitochondria, wherein it ultimately forms pores in the OMM. We have previously shown that during anoikis, Bax activation occurs in distinct stages before MOMP; an initial, reversible translocation to the mitochondria is followed by irreversible activation, concomitant with cytochrome-c release. 10, 11, 13 The second stage of activation, which occurs as the cryptic N-terminal epitopes become exposed, was found to equate with epithelial cell commitment to apoptosis. A number of other studies have also shown that Bax recruitment to the OMM does not necessarily mean that MOMP and cell death are inevitable. 21, 22 Together, these data indicate that separate signalling events control Bax translocation and its subsequent activation into a cytochrome-c-releasing pore. Our present data indicate that the second step of this process involves p38MAPK.
p38MAPKs are activated in response to a wide variety of cellular stresses and can regulate apoptosis through phosphorylation of downstream targets. 23 Many of the wellcharacterised p38MAPK targets are transcription factors. For example, activation of p38MAPK in response to DNA damage can induce p53-mediated upregulation of the proapoptotic BH3-only protein, Noxa. 24 In intestinal epithelial cells, p38MAPK-dependent upregulation of Fas ligand occurs after detachment from ECM to promote anoikis. 25 However, MEC anoikis does not require new gene expression. 26 In the present study, we showed that ATF2, a transcription factor substrate of p38MAPK, was not activated in response to ECM-withdrawal, but was after treatment with anisomycin. Although we saw p38MAPK-dependent phosphorylation of Hsp27 after detachment from ECM, we do not yet know what are the relevant substrates for the regulation of anoikis. A number of studies have implicated p38MAPK as a direct regulator of Bax. In cardiomyocytes, p38MAPK activity has been shown to be required for mitochondrial translocation of Bax in response to ischaemia. 27 Another study has suggested that p38MAPK and JNK can directly phosphorylate Bax in HepG2 cells following a variety of stresses, including UV irradiation and etoposide. 28 This phosphorylation by p38MAPK was suggested to regulate Bax mitochondrial translocation. However, our data indicate that p38MAPK activity was not required for mitochondrial association of Bax after loss of ECM attachment, a step that is regulated by adhesion-dependent tyrosine kinase signalling (J Keeble and AP Gilmore, unpublished data). Rather, p38MAPK was required for Bax that is already associated with the OMM, and present in a high molecular weight complex, to activate into a cytochrome-c-releasing pore. We found that inhibiting p38MAPK prevented apoptosis in response to a number of stimuli and also reduced the small amount of caspase activation seen in untreated cells. It is noteworthy that mitochondrial localisation of p38MAPK was observed in a small proportion of adherent cells that were not treated with any apoptotic stimulus (supplemental Figure 2b) . These data imply that p38MAPK may have a general role in apoptosis during normal cell turnover, as well as in response to specific stress stimuli. To date, phosphorylation of Bax by p38MAPK has not been detected in our system.
The members of the MAPK family respond to a wide range of stimuli, and yet it is well established that specific stimuli result in a restricted set of substrates and effectors becoming activated. 29 Our data suggest that p38MAPK activation during anoikis results in the activation of distinct set of substrates compared with anisomycin treatment, and this may be because of a restricted subcellular localisation. Specificity of MAP kinase signalling can be regulated by scaffold proteins, not only through recruiting both substrates and upstream activators but also by restricting MAPK localisation to particular subcellular compartments. Multiple scaffolds have been identified for ERK (for example, b-Arrestins, kinase suppressor of Ras, MEKK 1) and JNK (for example, filamin and JNK-interacting proteins (JIPs) 1-4). 30, 31 However, there are relatively few known p38MAPK scaffolds, with JIP2 and JIP4 reported to bind to and possibly regulate localisation of p38MAPK activity. [32] [33] [34] Osmosensing scaffold for MEKK3 (OSM) has also been shown to act as a p38MAPK scaffold. 35 OSM responds to osmotic stress by recruiting p38MAPK and Rac to membrane ruffles, wherein they co-operate to reorganise the actin cytoskeleton. In a similar way, our data showed that p38MAPK activated during anoikis was recruited into a mitochondrial membrane-associated, high molecular weight complex. This recruitment has a role in the commit-ment of MECs to apoptosis, as shown when we bypassed the normal recruitment of p38MAPK by targeting it to mitochondria using the tail anchor sequence of Bcl-X L . Similar use of artificial scaffolds has been previously shown to direct MAPK signalling in yeast. 36, 37 To date, no MAPK scaffold proteins have been characterised that direct signalling to mitochondria. 30 Thus, the membrane-associated complex that we observe in detached cells may contain novel p38MAPK-interacting proteins that direct a specific stress response to control apoptosis commitment.
Resistance to anoikis is an important factor in cancer metastasis. 8 We have identified a novel pathway of Bax regulation involving mitochondrial recruitment of p38MAPK. Together, our data suggest that p38MAPK acts as part of a novel mitochondrial complex to regulate Bax activation during anoikis. It will now be important to identify components of this complex.
Materials and Methods
Reagents and antibodies. Acrylamide and sodium dodecyl sulphate were obtained from Bio-Rad. b-mercaptoethanol, dithiothreitol, Tricine, Bis/Tris, aminocaproic acid, CHAPS, n-octylglucoside, Coomassie brilliant blue G-250 and poly-2-hydroxyethyl methacrylate (poly-HEMA) were obtained from Sigma. Triton X-100 was purchased from BDH. Protease Inhibitor Cocktail (539131), staurosporine, anisomycin, p38 inhibitor (SB203580) and JNK inhibitor (SP600125) were obtained from Calbiochem.
The following antibodies were used: Bax monoclonal 5B7 (B9054) and Actin purchased from Sigma; anti-BaxN20 (06-499) obtained from Upstate Biotechnology; polyclonal BaxD21 (sc-6236), p38b (E20) and ERK (C-14) purchased from Santa Cruz; Bid (AF860) and cleaved caspase- The following vectors and cDNAs were used: the yellow fluorescent protein (YFP) and YFP-Bax constructs have been described previously (Upton et al 11 ). Expression constructs encoding p38a, p38b, MAP kinase kinase 3(MKK3) and MKK6 were kindly provided by Dr Alan Whitmarsh, University of Manchester, UK. Mitochondrial targeting of proteins was achieved by creating fusion constructs using the Bcl-X L C-terminal membrane anchor sequence (XT). siRNA oligos against p38MAPKa were obtained from Ambion.
Cell culture and transfection. Fsk-7 cells, a mouse MEC line, were cultured as previously described. 12 Expression vectors were transfected into FSK-7 using Lipofectamine and Plus reagent, as previously described. 10 Cells were treated with 10 mM staurosporine, 10 mM anisomycin, 10 mM JNK inhibitor (SP600125) or 1.0 mM p38 inhibitor (SB203580); control cells were treated with vehicle (DMSO) alone. For anoikis studies, cells were plated onto the non-adherent substratum poly-HEMA; control cells were plated onto glass coverslips. siRNA transfections were performed using Lipofectamine 2000. Quantitative immunoblotting was performed using the Li-Cor Odyssey, as previously described. 13 Cell Fractionation and blue native polyacrylamide gel electrophoresis (BN-PAGE). Adherent and detached Fsk-7 cells were subfractionated into a cytosolic and membrane fractions, as described. 10 Membrane pellets were extracted in 1% CHAPS, 10% glycerol, 0.5 M aminocaproic acid in 50 mM Bis/Tris, pH 7.0, containing protease inhibitors and left on ice for 10 min before centrifuging at 1 00 000 Â g for 30 min. Two-dimensional (2D) blue native electrophoresis was performed, as previously described. 13 Immunodetection was performed by SuperSignal chemiluminesence (Pierce).
Immunofluorescence and imaging. For imaging, cells on coverslips were fixed using 4% formaldehyde in PBS and permeabilised using 0.5% Triton X-100/ PBS. Non-adherent cells were cytospun onto polysine-coated slides before fixation and permeabilisation, as described above. Cells were immunostained using primary antibodies followed by fluorophore-conjugated goat anti-IgG secondary antibodies (Molecular Probes). Nuclei were stained using 1 mg/ml Hoechst 33258 dye. Images were collected on an Olympus IX70 microscope, equipped with a Deltavision imaging system, using a 100 Â PLAN-APO 1.4NA objective. Images were processed by constrained iterative deconvolution on softWoRxTM software (Applied Precision).
For quantification of cell phenotypes, cells were visualised on an Axioplan 2 imaging microscope using a 63 Â 1.4NA Plan Apochromat objective (Zeiss MicroImaging). For transfection experiments, only the transfected cells were counted. A minimum of 300 cells were counted per condition.
